Drug Guidance for Subsidy 16/09/2025 Sotorasib for previously treated KRAS G12C-mutated locally advanced or metastatic non-small-cell lung cancer NRThe Ministry of Health’s Drug Advisory Committee has not recommended sotorasib for inclusion... See all × 16/09/2025 Sotorasib for previously treated KRAS G12C-mutated locally advanced or metastatic non-small-cell lung cancer NRThe Ministry of Health’s Drug Advisory Committee has not recommended sotorasib for inclusion on the MOH List of Subsidised Drugs for previously treated Kirsten Rat Sarcoma glycine-to-cysteine at Codon 12 (KRAS G12C)-mutated locally advanced or metastatic non-small-cell lung cancer. The decision was based on lack of clinical- and cost-effectiveness of sotorasib compared with docetaxel, and the unacceptable price-volume agreement proposed by the company. Clinical indication, subsidy class and MediShield Life claim limit for sotorasib are provided in the Annex.
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Tablet, Film Coated 120 mg National Cancer Centre National University Hospital